PRVA

PRVA

USD

Privia Health Group Inc. Common Stock

$23.060-0.200 (-0.860%)

Prix en Temps Réel

Healthcare
Health Information Services
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$23.260

Haut

$23.310

Bas

$23.060

Volume

0.00M

Fondamentaux de l'Entreprise

Capitalisation Boursière

2.8B

Industrie

Health Information Services

Pays

United States

Statistiques de Trading

Volume Moyen

0.83M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $15.92Actuel $23.060Haut $26.037

Rapport d'Analyse IA

Dernière mise à jour: 29 avr. 2025
Généré par l'IASource des Données: Yahoo Finance, Bloomberg, SEC

PRVA (Privia Health Group Inc. Common Stock): Checking the Pulse on Recent Analyst Views and Price Action

Stock Symbol: PRVA Generate Date: 2025-04-29 18:57:51

Let's take a look at what's been happening with Privia Health Group lately, based on the latest news and how the stock price has been moving.

What Analysts Are Saying

The recent buzz around PRVA seems mostly positive, at least from the analyst crowd. We've seen a few different firms weigh in over the past month or so.

  • JMP Securities just recently (April 28th) stuck with their "Market Outperform" rating and kept their price target at a solid $29. That's a pretty strong vote of confidence.
  • Before that, Baird (April 15th) also kept their "Outperform" rating but actually bumped up their price target a bit, moving it from $24 to $26. That's another positive sign, showing they see more room for the stock to run.
  • Barclays (April 10th) maintained a more neutral "Equal-Weight" rating, but they did raise their price target from $21 to $23. So, even a more cautious view saw enough improvement to lift their target.
  • Also on April 10th, Truist Securities kept their "Buy" rating, though they slightly adjusted their target from $27 to $28. Still a "Buy," which is good.
  • Needham, also on April 10th, reiterated their "Buy" rating and held their price target steady at $30.

Putting it simply, the general feeling from these analysts is leaning positive. Most have a "Buy" or "Outperform" rating, and several have actually raised their price targets recently. This tells us that the pros who follow this company think things are heading in the right direction, or at least have potential.

How the Stock Price Has Been Acting

Looking back over the last month or so, the price of PRVA has seen a bit of a rollercoaster, but it seems to have found a recent range.

Back in late March and early April, the stock dipped down towards the $22 mark, even touching below that briefly. Then, around mid-April, right when some of that analyst news started hitting, the price bounced back up, climbing into the $24 range.

More recently, since about April 15th, the price has pulled back a little from those highs and seems to be trading mostly between $22.50 and $23.50. The last recorded price point shows it closing around $23.58.

So, we saw a dip, a bounce, and now it looks like it's consolidating or trading sideways in the low $23s.

What This Might Mean and Some Ideas

Okay, let's try to connect the dots. We have analysts who are mostly positive, raising targets, and a stock price that recently bounced but is now hanging around the $23-$23.50 area.

The AI prediction model also chimes in, suggesting small upward moves are likely in the very near term: predicting a tiny gain today (+0.34%), then slightly larger gains tomorrow (+2.44%) and the day after (+2.64%). This aligns with the generally positive analyst sentiment.

Based on this mix – positive analyst views, a recent price bounce, and AI predicting continued upward movement – the near-term picture seems to lean positive. It doesn't look like a runaway train right now, but the underlying sentiment and predictions suggest potential for the price to climb from here.

Potential Entry Consideration: If you were thinking about this stock, the current price area, around $23.58, could be a point to consider. It's right where the stock is trading now, and the AI sees it moving up from here. The AI's recommendation data also pointed to potential entry spots slightly lower, around $23.16 or $23.26. If the stock dips back towards that $23.20-$23.30 zone, that might also look interesting, as it's been a recent trading area.

Potential Exit/Stop-Loss Consideration: Managing risk is always smart. The AI recommendation data suggests a potential take-profit level around $24.63. This is above the recent trading range and could be a spot to consider if the stock climbs. For managing downside risk, the AI suggests a stop-loss at $20.90. This is well below recent lows and gives the stock plenty of room to move without triggering a stop unless there's a significant drop.

A Little About the Company

Just to add some context, Privia Health Group is in the Healthcare sector, specifically focusing on Health Information Services. They work with doctors, health plans, and hospitals, basically helping physician practices run better, use technology, and manage patient care more effectively, especially in value-based care models. The analyst views and price movements are likely tied to how well the market thinks they are executing on this strategy and growing their business in the healthcare space.


Disclaimer: This report is for informational purposes only and is based on the provided data. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research or consult with a qualified financial advisor before making any investment decisions.

Actualités Connexes

Analyst Upgrades

JMP Securities Reiterates Market Outperform on Privia Health Gr, Maintains $29 Price Target

JMP Securities analyst Constantine Davides reiterates Privia Health Gr with a Market Outperform and maintains $29 price target.

Voir plus
JMP Securities Reiterates Market Outperform on Privia Health Gr, Maintains $29 Price Target
Analyst Upgrades

Baird Maintains Outperform on Privia Health Gr, Raises Price Target to $26

Baird analyst Michael Ha maintains Privia Health Gr with a Outperform and raises the price target from $24 to $26.

Voir plus
Baird Maintains Outperform on Privia Health Gr, Raises Price Target to $26
Analyst Upgrades

Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $23

Barclays analyst Andrew Mok maintains Privia Health Gr with a Equal-Weight and raises the price target from $21 to $23.

Voir plus
Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $23
Analyst Upgrades

Truist Securities Maintains Buy on Privia Health Gr, Lowers Price Target to $28

Truist Securities analyst Jailendra Singh maintains Privia Health Gr with a Buy and lowers the price target from $27 to $28.

Voir plus
Truist Securities Maintains Buy on Privia Health Gr, Lowers Price Target to $28
Analyst Upgrades

Needham Reiterates Buy on Privia Health Gr, Maintains $30 Price Target

Needham analyst Matthew Sheerin reiterates Privia Health Gr with a Buy and maintains $30 price target.

Voir plus
Needham Reiterates Buy on Privia Health Gr, Maintains $30 Price Target

Prédiction IABeta

Recommandation IA

Haussier

Mis à jour le: 5 mai 2025, 17:42

BaissierNeutreHaussier

72.5% Confiance

Risque et Trading

Niveau de Risque3/5
Risque Moyen
Adapté Pour
Modéré
Guide de Trading

Point d'Entrée

$23.29

Prise de Bénéfices

$23.78

Stop Loss

$20.98

Facteurs Clés

Le PDI 4.6 est au-dessus du MDI 3.4 avec un ADX de 18.9, suggérant une tendance haussière
Le cours actuel est extrêmement proche du niveau de support ($23.27), suggérant une forte opportunité d'achat
Le volume de transactions est 5.3x la moyenne (7,965), indiquant une pression d'achat extrêmement forte
Le MACD 0.0279 est au-dessus de la ligne de signal 0.0248, indiquant un croisement haussier

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.